

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Michael Cuenod

Examiner: Katherine Salmon

APPLICATION NO: 10/586,071

Art Unit: 1634

FILED: January 14, 2005

FOR: Diagnostic and Treatment of a Mental Disorder

SUPPLEMENTAL RESPONSE TO RESTRICTION REQUIREMENT


In response to the new Restriction Requirement of August 31, 2010, a response to which is due by September 30, 2010, Applicants elect the claims of Group I, claims 1-8 and 40-42, drawn to diagnostic methods determining the level of expression of a gene wherein the level of expression is nucleic acid expression. This election is without traverse.

In response to the requirement for a species election among the different genes involved in regulating the intracellular GSH level, Applicants elect the gene glutamate-cysteine ligase (GCL). The claims readable on the elected species are claims 1-3, 5-8 and 40-42. This species election is without traverse.

Should the Examiner have any questions, please contact the undersigned attorney. An early and favorable action on the merits is respectfully requested.

Respectfully submitted,

Novartis Institutes for BioMedical Research, Inc.
220 Massachusetts Ave
Cambridge, MA 02139
(617) 871-3346



John T. Prince
Attorney for Applicant
Reg. No. 43,019

Date: September 23, 2010